Healthcare CFOs see fresh wave of M&A in 2021: BDO poll

Financial distress, a desire to expand into new service lines and efforts to close infrastructure gaps are expected to fuel the upturn, according to the consultants.

By Susan Kelly • Jan. 12, 2021

Medtech M&A to take off after pandemic slowed deals in 2020: EY

Dealmaking in 2021 will be fueled by financial firepower across the industry at an "all-time high" of nearly $500 billion, according to the consultants.

By Ricky Zipp • Jan. 10, 2021

PerkinElmer inks $591M Oxford Immunotec buy to challenge Qiagen in TB market

The deal comes amid a flurry of medtech M&A during the first week of 2021. Hologic inked two acquisitions in the women's health space and Stryker said it would buy sensor maker OrthoSensor.

By Nick Paul Taylor • Jan. 8, 2021

Hologic's $230M Biotheranostics buy its 2nd M&A deal of 2021

Some Wall Street analysts were surprised by the target, but others suggested the move could strengthen the company for a post-coronavirus environment.

By Ricky Zipp • Jan. 6, 2021

Stryker buys sensor maker in bet on wearables in orthopaedics

OrthoSensor's technology could complement the medtech's robotics platform and boost its data analytics capabilities, SVB Leerink analysts said in a Tuesday note on the acquisition.

By Susan Kelly • Jan. 5, 2021

Hologic eyes future post COVID-19 with Somatex Medical tuck-in

The medical device maker is bulking up its women's health business as molecular diagnostics sales surge due to the pandemic. Wall Street analysts have said these lines are equipped to withstand market uncertainties.

By Susan Kelly • Jan. 5, 2021

The top medtech deals of 2020 (and one that got away)

M&A activity bounced back in the second half of the year, with deals ranging from Teladoc's $18.5 billion Livongo buy to Stryker's drawn-out $4 billion acquisition of Wright Medical.

By Susan Kelly • Jan. 4, 2021

Hospital giant Tenet goes big on ASCs

A shift in focus to outpatient settings is also occurring among medical device companies. Both Stryker and Zimmer Biomet have made ASCs more of a priority over the last several years.

By Samantha Liss • Dec. 22, 2020

Philips buys cardiac monitoring company BioTelemetry in $2.8B deal

The Dutch conglomerate said that the move will expand its remote patient monitoring business beyond the hospital space. Baird called the pact a surprise but the valuation fair.

By Ricky Zipp • Dec. 18, 2020

Olympus to pay $300M to buy Veran for lung navigation system

The deal is for $300 million up front, with another $40 million tied to an undisclosed milestone.

By Nick Paul Taylor • Dec. 7, 2020

LivaNova offloads heart valve tech to Gyrus Capital following investor pressure

The announcement comes shortly after activist shareholder PrimeStone Capital demanded LivaNova sell or close the "likely loss-making" business line.

By Maria Rachal • Dec. 3, 2020

Zimmer puts up $250M in surgical device deal, Boston Scientific nets $800M in BTG pharma sell-off

The pandemic hasn't stopped M&A in the medtech industry, with Zimmer Biomet adding to its sternal closure device lineup via A&E Medical and Boston Scientific streamlining business with a sale to specialty pharma group SERB.

By Nick Paul Taylor • Dec. 1, 2020

Healthcare deals in Q4 predicted to fall from record-setting Q3: report

Market research firm CB Insights believes the drop will carry over into the digital health sector too, an area that's seen historic investor interest in 2020 amid the coronavirus pandemic.

By Rebecca Pifer • Nov. 25, 2020

Zimmer reports record robot installs, ASC-inspired M&A

While the company benefited from a rebound in elective procedures, execs warned investors the recovery slowed as the third quarter drew to a close.

By Nick Paul Taylor • Nov. 6, 2020

Stryker closes Wright Medical acquisition after year-long wait

The Kalamazoo, Michigan-based medtech highlighted the shoulder, elbow, wrist, hand, foot and ankle devices it's gained, along with preoperative planning technology, now that the deal is final.

By Maria Rachal • Updated Nov. 11, 2020

Illumina defends Grail valuation amid much cheaper Exact-Thrive deal

The biotech defended its $8 billion purchase price against Exact Sciences' $2.15 billion cancer screening takeout agreement announced this week, arguing Grail has more data and is likely to be first to market.

By Nick Paul Taylor • Oct. 30, 2020

Medtronic acquires thyroid surgery tech in 7th tuck-in deal of 2020

An addition to the medtech's pandemic-battered ENT business, Ai Biomed's PTeye system won De Novo authorization from FDA in 2018 for its ability to help surgeons spare important calcium-regulating tissue during procedures.

By Maria Rachal • Oct. 29, 2020

Teleflex lines up $525M to buy hemostat specialist Z-Medica

The medtech predicts the trauma surgery and emergency medicine-focused products will begin adding up to $70 million in revenue next year, providing growth drivers outside its key interventional urology segment.

By Maria Rachal • Oct. 29, 2020

Smith & Nephew lays path to 10% growth for acquired Integra assets

The medtech is moving deeper into the extremity orthopaedics turf fought over by the likes of Zimmer Biomet and Stryker acquisition target Wright Medical.

By Nick Paul Taylor • Oct. 29, 2020

Exact Sciences stock jumps on cancer detection deals for Thrive, Base Genomics

The cancer diagnostics company is aiming to bolster its technology pipeline weeks after Illumina put up $8 billion to acquire liquid biopsy developer Grail.

By Nick Paul Taylor , Maria Rachal • Updated Oct. 27, 2020

Stryker buyout of Wright poised to pass 1-year mark without closing

CEO Kevin Lobo said last month the $5.4 billion buyout, which has faced antitrust hurdles, was on track to be finalized in early October.  

By Maria Rachal • Oct. 26, 2020

Steris inks $850M deal for Key Surgical adds to medtech M&A wave

CEO Walter Rosebrough gave a nod to current low interest rates but said Steris had been looking at this potential transaction "for years, not months."

By Susan Kelly • Oct. 7, 2020

Analysts predict Zimmer Biomet M&A in 2021 to speed growth

The medtech is likely to initially target private orthopaedic companies worth up to $300 million, Needham analysts specified. The spine and dental businesses, meanwhile, could be on the chopping block.

By Nick Paul Taylor • Oct. 7, 2020

M&A on horizon as deep-pocketed medtechs eye distressed assets: EY

The combination of smaller companies questioning their pandemic survival and larger companies with considerable capital may spark a buying surge, the consultancy said in its annual medtech report.

By Nick Paul Taylor • Oct. 6, 2020

Medtronic to expand dialysis access position with Avenu Medical buyout

The deal is the second tuck-in acquisition this year for the medtech's peripheral vascular business and the company's sixth overall, following additions to insulin delivery, surgery and spinal cord stimulation offerings.

By Maria Rachal • Updated Sept. 30, 2020